vs

Side-by-side financial comparison of Clearfield, Inc. (CLFD) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($37.2M vs $34.3M, roughly 1.1× Clearfield, Inc.). On growth, Clearfield, Inc. posted the faster year-over-year revenue change (-3.2% vs -57.1%). Over the past eight quarters, Clearfield, Inc.'s revenue compounded faster (-3.5% CAGR vs -46.5%).

Clearfield, Inc. is a company headquartered in Minneapolis, Minnesota. The company produces fiber optic products.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CLFD vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.1× larger
ORGO
$37.2M
$34.3M
CLFD
Growing faster (revenue YoY)
CLFD
CLFD
+53.9% gap
CLFD
-3.2%
-57.1%
ORGO
Faster 2-yr revenue CAGR
CLFD
CLFD
Annualised
CLFD
-3.5%
-46.5%
ORGO

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLFD
CLFD
ORGO
ORGO
Revenue
$34.3M
$37.2M
Net Profit
$-614.0K
Gross Margin
33.2%
30.8%
Operating Margin
-5.3%
-185.1%
Net Margin
-1.8%
Revenue YoY
-3.2%
-57.1%
Net Profit YoY
67.8%
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLFD
CLFD
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$34.3M
$225.6M
Q3 25
$23.4M
$150.9M
Q2 25
$49.9M
$101.0M
Q1 25
$47.2M
$86.7M
Q4 24
$29.7M
$126.7M
Q3 24
$5.6M
$115.2M
Q2 24
$48.8M
$130.2M
Net Profit
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
$-614.0K
$43.7M
Q3 25
$-9.1M
$21.6M
Q2 25
$1.6M
$-9.4M
Q1 25
$1.3M
$-18.8M
Q4 24
$-1.9M
$7.7M
Q3 24
$12.3M
Q2 24
$-447.0K
$-17.0M
Gross Margin
CLFD
CLFD
ORGO
ORGO
Q1 26
30.8%
Q4 25
33.2%
Q3 25
53.2%
Q2 25
30.5%
Q1 25
30.1%
72.6%
Q4 24
29.2%
75.5%
Q3 24
76.7%
Q2 24
21.9%
77.6%
Operating Margin
CLFD
CLFD
ORGO
ORGO
Q1 26
-185.1%
Q4 25
-5.3%
28.1%
Q3 25
10.3%
13.7%
Q2 25
3.0%
-12.5%
Q1 25
0.6%
-30.9%
Q4 24
-6.9%
8.1%
Q3 24
5.4%
Q2 24
-4.7%
-10.7%
Net Margin
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
-1.8%
19.4%
Q3 25
-38.8%
14.3%
Q2 25
3.2%
-9.3%
Q1 25
2.8%
-21.7%
Q4 24
-6.4%
6.1%
Q3 24
10.7%
Q2 24
-0.9%
-13.1%
EPS (diluted)
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
$-0.04
$0.31
Q3 25
$-0.65
$0.11
Q2 25
$0.11
$-0.10
Q1 25
$0.09
$-0.17
Q4 24
$-0.13
$0.05
Q3 24
$0.09
Q2 24
$-0.04
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLFD
CLFD
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$96.4M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$249.7M
Total Assets
$268.1M
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLFD
CLFD
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$96.4M
$93.7M
Q3 25
$106.0M
$63.7M
Q2 25
$117.2M
$73.1M
Q1 25
$112.0M
$110.0M
Q4 24
$113.0M
$135.6M
Q3 24
$129.0M
$94.3M
Q2 24
$123.8M
$89.9M
Total Debt
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$2.2M
$62.3M
Q2 24
$2.1M
$63.8M
Stockholders' Equity
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
$249.7M
$300.1M
Q3 25
$256.2M
$255.1M
Q2 25
$264.5M
$233.2M
Q1 25
$265.9M
$242.9M
Q4 24
$267.4M
$262.9M
Q3 24
$275.8M
$278.5M
Q2 24
$274.6M
$263.5M
Total Assets
CLFD
CLFD
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$268.1M
$598.7M
Q3 25
$306.2M
$509.8M
Q2 25
$314.7M
$461.1M
Q1 25
$310.9M
$467.4M
Q4 24
$303.2M
$497.9M
Q3 24
$315.3M
$446.3M
Q2 24
$318.1M
$443.2M
Debt / Equity
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.01×
0.22×
Q2 24
0.01×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLFD
CLFD
ORGO
ORGO
Operating Cash FlowLast quarter
$-1.4M
Free Cash FlowOCF − Capex
$-2.4M
FCF MarginFCF / Revenue
-7.1%
Capex IntensityCapex / Revenue
2.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
$-1.4M
$39.4M
Q3 25
$3.1M
Q2 25
$7.9M
$-32.9M
Q1 25
$3.0M
$-19.9M
Q4 24
$7.2M
$10.9M
Q3 24
$22.2M
$8.7M
Q2 24
$4.0M
$4.7M
Free Cash Flow
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
$-2.4M
$34.8M
Q3 25
$844.0K
Q2 25
$7.5M
$-36.5M
Q1 25
$654.0K
$-23.6M
Q4 24
$5.1M
$7.6M
Q3 24
$18.2M
$6.1M
Q2 24
$2.8M
$2.9M
FCF Margin
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
-7.1%
15.4%
Q3 25
0.6%
Q2 25
15.1%
-36.1%
Q1 25
1.4%
-27.2%
Q4 24
17.1%
6.0%
Q3 24
323.0%
5.3%
Q2 24
5.8%
2.2%
Capex Intensity
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
2.9%
2.1%
Q3 25
2.0%
1.5%
Q2 25
0.8%
3.6%
Q1 25
5.1%
4.2%
Q4 24
7.0%
2.7%
Q3 24
71.4%
2.2%
Q2 24
2.5%
1.4%
Cash Conversion
CLFD
CLFD
ORGO
ORGO
Q1 26
Q4 25
0.90×
Q3 25
0.14×
Q2 25
4.93×
Q1 25
2.30×
Q4 24
1.43×
Q3 24
0.71×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons